Thermo Fisher Scientific Announces New Strategic Partnership with Megaware
Apr 18 2008
The two companies will market a new comprehensive end-to-end software solution which provides bioequivalence functionality on a single platform to help speed up and manage clinical trials. Rapid market
growth in generic drug production is driving the requirement for fast efficient bioequivalence studies to meet FDA ANDA guidelines (Abbreviated New Drug Applications). A unified software solution will
aggregate disparate software systems for organisations that demand tools to speed service and management of this critical and regulated IPO.
Thermo Fisher and Megaware will jointly sell, market and support the new solution in the field. Thermo Fisher will bring its bioanalytical expertise to the partnership and Megaware, with headquarters in
Westborough, MA and Mumbai, India, will deliver the end-to-end technological focus combined with on-the-ground market knowledge. The new solution will offer higher throughput, greater levels of compliance
and standardisation of bioequivalence processes.
International Labmate 48.2 - March 2023
In This Edition Chromatography Articles - On-Column Sample Focussing: a Personal Perspective Mass Spectrometry & Spectroscopy Articles - Multi-scale, multi-modal and operando imaging wi...
View all digital editions
Mar 28 2023 Milan, Italy
Apr 02 2023 Monterey, CA, USA
Apr 11 2023 Moscow, Russia
Microbiology Society Annual Conference 2023
Apr 17 2023 Birmingham, UK
Apr 18 2023 Kintex, South Korea